Research at the Max Planck Institute of Psychiatry

Research at the Max Planck Institute of Psychiatry

Research Focus

The main goal of the Max Planck Institute of Psychiatry is to uphold a uniquely close interaction between basic science, clinical research and clinical services in order to gain knowledge about and understanding of the causes of psychiatric disorders. This knowledge can then be applied in the development of novel diagnostic possibilities as well as therapeutic and preventive approaches. Stress-related disorders, such as major depression and anxiety disorders, are our main research and clinical focus.

Our overarching aim is to contribute to a new, biology-based taxonomy of psychiatric disease and to develop treatments and preventive strategies targeted to the underlying biological disturbance.
Our goal is to determine genetic risk factors and their interaction with environmental exposures. In addition, we aim at dissecting epigenetic mechanisms and neural circuits underlying the etiology and pathophysiology of stress-related neuropsychiatric disorders. more
The main focus of this research group is to study the impact of acute and chronic stress on the body during different developmental stages. Specifically, we are interested in the behavioral, neuroendocrine and molecular basis of individual stress vulnerability and resilience. more
Neuronal migration is a fundamental step in the development of the central nervous system. We aim at understanding the biological mechanisms and therefore identifying potential therapies for cortical malformations.
Our group focuses on the quantitative analysis of genetic data and transcriptomic data in psychiatric disease and its treatment. We also work on metabolomic as well as proteomic data in the same spirit. Furthermore, we have an interest in other phenotypes, such as dyslexia/dyscalculia, cardiovascular disease, and multiple sclerosis, to name some examples.
Research in our laboratory centers on the identification of biosignatures for psychiatric disorders and the antidepressant drug response. Sensitive high throughput proteomics and metabolomics platforms are used for data generation providing a rich source for in silico pathway analyses.
We focus on the biological mechanisms of psychotherapy and the use of biomarkers to optimize the psycho- and pharmacological treatments to individual patient characteristics.
The research groups of the institute are supported by several scientific Core Units. The spectrum is under permanent development according to the requirements of the scientists.
Go to Editor View